| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/26/2012 | US20120021425 Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571 |
| 01/26/2012 | US20120021080 Production and Extraction of Procyanidins from Plant Cell Cultures |
| 01/26/2012 | US20120021079 Garcinia Mangostana L. and Iridoid Based Formulations |
| 01/26/2012 | US20120021055 Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
| 01/26/2012 | US20120021050 Nanoparticle formulated glycolipid antigens for immunotherapy |
| 01/26/2012 | US20120021047 Id-1 Gene and Gene Products as Therapeutic Targets for Treatment of Breast Cancer and Other Types of Carcinoma |
| 01/26/2012 | US20120021045 Methods for Inhibiting Cancer Cell Proliferation |
| 01/26/2012 | US20120021044 Novel Cationic Lipid, A Preparation Method of the Same and A Delivery System Comprising the Same |
| 01/26/2012 | US20120021043 Nucleic Acids Comprising formula (NuGlXmGnNv)a and Derivatives Thereof as Immunostimulating Agent/Adjuvant |
| 01/26/2012 | US20120021036 Composite nanostructures and methods for making and using them |
| 01/26/2012 | US20120021012 Novel pharmaceutical uses for nanoparticles |
| 01/26/2012 | US20120021007 Nitric oxide furoxan derivative compounds endowed with antitumoral activity |
| 01/26/2012 | US20120021006 Egfr-homing double-stranded rna vector for systemic cancer treatment |
| 01/26/2012 | US20120020998 Plasmacytoid dendritic cell line used in active or adoptive cell therapy |
| 01/26/2012 | US20120020991 Prodomain modulators of adam 10 |
| 01/26/2012 | US20120020989 Methods of treating colorectal cancer |
| 01/26/2012 | US20120020984 Genetic Markers for Predicting Responsiveness to Combination Therapy |
| 01/26/2012 | US20120020983 Emp2 antibodies and their therapeutic uses |
| 01/26/2012 | US20120020981 Anti-IL6/IL-6R Antibodies and Methods of Use Thereof |
| 01/26/2012 | US20120020978 Antibodies against fatty acid synthase |
| 01/26/2012 | US20120020977 Pancreatic cancer genes |
| 01/26/2012 | US20120020967 VEGF antibodies comprising modular recognition domains |
| 01/26/2012 | US20120020966 Multispecific antibody targeting and multivalency through modular recognition domains |
| 01/26/2012 | US20120020965 Molecules that bind CD180, compositions and methods of use |
| 01/26/2012 | US20120020962 Method of depleting regulatory t cell |
| 01/26/2012 | US20120020961 Methods and compositions for liver cancer therapy |
| 01/26/2012 | US20120020960 Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer |
| 01/26/2012 | US20120020959 Use of the sparc microenvironment signature in the treatment of cancer |
| 01/26/2012 | US20120020956 Activation of sodium potassium atpase |
| 01/26/2012 | US20120020953 Diagnosis and treatment of cancer |
| 01/26/2012 | US20120020951 Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects |
| 01/26/2012 | US20120020926 Composition comprising caftaric acid and/or derivatives thereof |
| 01/26/2012 | US20120020915 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System |
| 01/26/2012 | US20120020914 Leukemia inhibitory factor (lif) for use in repressing human papillomavirus (hpv) transcription |
| 01/26/2012 | US20120020912 Prostate cancer vaccine |
| 01/26/2012 | US20120020889 Polypeptides Targeting Vascular Endothelial Growth Factor Receptor-2 and Alpha V Beta 3 Integrin |
| 01/26/2012 | US20120020888 Biomarker |
| 01/26/2012 | US20120020885 MHC-Less cells |
| 01/26/2012 | US20120020882 Peptide-based compounds |
| 01/26/2012 | US20120020880 Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44 |
| 01/26/2012 | US20120020879 Process, composition and method for anion deposition into ferritin for therapeutic and other use |
| 01/26/2012 | US20120020878 Fusogenic properties of saposin c and related proteins and peptides for application to transmembrane drug delivery systems |
| 01/26/2012 | US20120020877 Process and intra-cervical device for the local release of drugs in the local-regional treatment of cervical cancer |
| 01/26/2012 | US20120020876 Hedgehog pathway inhibitors |
| 01/26/2012 | CA2809405A1 Compounds for photodynamic therapy |
| 01/26/2012 | CA2806258A1 Fused heterocyclic compound and application thereof |
| 01/26/2012 | CA2806076A1 Anti-tumor antigen antibodies and methods of use |
| 01/26/2012 | CA2806058A1 Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects |
| 01/26/2012 | CA2806051A1 Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anticancer agent, method for producing and using same |
| 01/26/2012 | CA2805994A1 Anti-cd19 antibody having adcc and cdc functions and improved glycosylation profile |
| 01/26/2012 | CA2805874A1 Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| 01/26/2012 | CA2805774A1 Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
| 01/26/2012 | CA2805745A1 Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease |
| 01/26/2012 | CA2805658A1 Combination therapy with mdm2 and efgr inhibitors |
| 01/26/2012 | CA2805567A1 Pyrimidine compounds as inhibitors of protein kinases ikk epsilon and/or tbk-1, processes for their preparation, and pharmaceutical compositions containing them |
| 01/26/2012 | CA2803948A1 Tubulysin analogues |
| 01/26/2012 | CA2803467A1 New aminopyrazoloquinazolines |
| 01/26/2012 | CA2801781A1 Protein kinase c inhibitors and uses thereof |
| 01/25/2012 | EP2409984A1 Dimeric IAP Antagonists |
| 01/25/2012 | EP2409983A1 Tubulysin analogues |
| 01/25/2012 | EP2409969A1 Pyrimidine urea derivatives as kinase inhibitors |
| 01/25/2012 | EP2409708A1 Compounds and methods for selectively targeting tumor-associated mucins |
| 01/25/2012 | EP2409706A1 Dihydropteridinones for the treatment of cancer diseases |
| 01/25/2012 | EP2409705A1 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| 01/25/2012 | EP2409704A2 c-Met modulators and methods of use |
| 01/25/2012 | EP2409703A1 Treatment with alpha7-selective ligands |
| 01/25/2012 | EP2409700A1 Methods of treatment using intravenous formulations comprising temozolomide |
| 01/25/2012 | EP2409698A1 Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition |
| 01/25/2012 | EP2409697A1 Medicaments Based on Dinuclear Ruthenium, Osmium and Iron Complexes Comprising Triply Bridging Thiolato, Selenolato, Alkoxo and/or Amido Ligands |
| 01/25/2012 | EP2408913A1 Neil3 peptides and vaccines including the same |
| 01/25/2012 | EP2408912A1 Foxm1 peptides and vaccines containing the same |
| 01/25/2012 | EP2408820A1 Humanised antibodies with anti-tumour activity |
| 01/25/2012 | EP2408819A2 High affinity t-cell receptor-like ny-eso-1 peptide antibodies, methods, and uses thereof |
| 01/25/2012 | EP2408779A1 Compounds and biological materials and uses thereof |
| 01/25/2012 | EP2408776A1 Use of a kinase inhibitor for the treatment of thymoma |
| 01/25/2012 | EP2408773A2 Inhibitors of pi3 kinase |
| 01/25/2012 | EP2408772A1 Compounds |
| 01/25/2012 | EP2408762A1 Hsp90 inhibiting indazole derivatives, compositions containing same and use thereof |
| 01/25/2012 | EP2408755A2 Psma-targeting compounds and uses thereof |
| 01/25/2012 | EP2408753A2 Compounds and methods for treating mammalian gastrointestinal microbial infections |
| 01/25/2012 | EP2408752A1 Substituted pyrimidines for the treatment of cancer |
| 01/25/2012 | EP2408479A1 Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
| 01/25/2012 | EP2408473A1 Vaccination methods |
| 01/25/2012 | EP2408465A2 Methods and compositions for the detection of cancer |
| 01/25/2012 | EP2408446A1 Use of pharmaceutical compositions containing mesembrenone |
| 01/25/2012 | EP2408445A1 Gold (iii) complexes with oligopeptides functionalized with sulfur donors and use thereof as antitumor agents |
| 01/25/2012 | EP2408300A1 Amino ester derivatives, salts thereof and methods of use |
| 01/25/2012 | EP2328890B1 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
| 01/25/2012 | EP2086938B1 Organic compounds |
| 01/25/2012 | EP2079743B1 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer |
| 01/25/2012 | EP2034017B1 Gene involved in immortalization of human cancer cell and use thereof |
| 01/25/2012 | EP1967188B1 Pharmaceutical preparation of an aqueous solution containing platinum complex |
| 01/25/2012 | EP1901729B1 Pharmaceutical formulations of hdac inhibitors |
| 01/25/2012 | EP1781639B1 Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| 01/25/2012 | EP1765778B1 N-sulfonylcarboximidamide apoptosis promoters |
| 01/25/2012 | EP1545613B9 Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 01/25/2012 | EP1503773B9 Hepatoprotective activity of 2 -p-hydroxybenzoylmussaenosidic acid |
| 01/25/2012 | EP1330456B9 N8,n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents |
| 01/25/2012 | EP1310494B1 PPAR (delta) ACTIVATORS |
| 01/25/2012 | EP1192253B1 Icbp90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer |